Reviews/Heart Failure Management/Vericiguat reduces events in worsening heart failure with reduced ejection fraction
Novel · HFM-NOVEL-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
One large, well-conducted randomised trial tested exactly this drug in exactly these patients and found that it modestly lowered the combined rate of heart-related death or hospitalisation for heart failure [11]. Several further analyses of that same trial agreed that the benefit held up across kidney function, blood pressure, how recently the patient was hospitalised, and natriuretic peptide levels [3],[4],[5],[6],[9],[10]. A small non-randomised study in a narrower group of patients pointed the same way [13]. The effect is not large, and when you look at the two parts of the combined outcome on their own, neither reached statistical significance [11]; most of the supporting evidence comes from re-examining the one trial rather than from fresh independent studies. The panel judged that this one solid trial supports the claim but does not yet settle it beyond doubt.
The pivotal phase 3 RCT [11] met its pre-specified primary endpoint, with the composite of cardiovascular death or heart failure hospitalisation occurring in 35.5% on vericiguat versus 38.5% on placebo (HR 0.90, 95% CI 0.82-0.98, P=0.02), in patients with EF <45% and recent worsening heart failure. Pre-specified subgroup analyses of the same trial found the direction of benefit preserved across renal function [4], baseline blood pressure [6], index-event timing [5], screening NT-proBNP trajectory [9] and health status [10]. External non-randomised corroboration comes from a 149-patient ACS cohort [13] (HR 0.31, 95% CI 0.10-0.96, P=0.041). A large single-arm real-world cohort reported a one-year composite incidence of 29.8% but has no comparator [12]. The contested point: The division is over how much weight one trial can bear: the composite is significant but borderline (upper CI bound 0.98, P=0.02) while its individual components were not (HFH HR 0.90, 0.81-1.00; CV death HR 0.93, 0.81-1.06) [11], and almost all corroboration is reanalysis of that same trial [3],[4],[5],[6],[7],[9],[10]. There is also heterogeneity at the extreme, with no benefit at NT-proBNP >8,000 pg/ml (HR 1.16, 0.94-1.41) [3].
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus is dominated by one pivotal trial: [3],[4],[5],[6],[7],[9],[10] are all reanalyses of VICTORIA [11]. The claim rests substantially on a single RCT rather than independent replication.
The pivotal effect is modest and borderline: [11] HR 0.90 with CI upper bound 0.98 and P=0.02, while the individual components were non-significant (HFH HR 0.90, CI 0.81-1.00; CV death HR 0.93, CI 0.81-1.06). The composite is carried by aggregation.
Where it remains uncertain. The effect is borderline and both components were individually non-significant [11], and the supporting corpus is largely reanalyses of the one trial [3],[4],[5],[6],[7],[9],[10] plus small non-randomised cohorts [12],[13].
Aleatory
The primary estimate sits close to the null boundary (HR 0.90, upper CI 0.98, P=0.02) [11], so sampling variation leaves a real chance the true effect is near-neutral.
Epistemic
A second randomised trial in this population is absent from the corpus; [3],[4],[5],[6],[7],[9],[10] all re-examine the one VICTORIA dataset [11].
Inferential
The claim is about the composite, which was significant [11], but neither HFH (HR 0.90, 0.81-1.00) nor CV death (HR 0.93, 0.81-1.06) reached significance individually, so attributing a specific mechanism of benefit is uncertain.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Confirms the composite reduction and bounds it by NT-proBNP (attenuated above 8,000 pg/ml).
“Vericiguat compared with placebo reduced the primary outcome of cardiovascular death (CVD) or heart failure hospitalization (HFH) in patients with HF with reduced ejection fraction (HFrEF) in the VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial.”
Panel auditInternal validity: high · scope of inference: Vericiguat's effect on the primary composite across the NT-proBNP spectrum in worsening HFrEF; benefit attenuates at very high NT-proBNP (>8,000 pg/ml).Key limitations: subgroup/interaction analysis · no net benefit above NT-proBNP 8,000 pg/ml · treatment-NT-proBNP interaction p=0.002
Shows the composite reduction is consistent across the spectrum of worsening-HF risk.
“Vericiguat was associated with reduced risk of the primary outcome overall and in all subgroups, without evidence of treatment heterogeneity.”
Panel auditInternal validity: high · scope of inference: Vericiguat's primary-outcome benefit across timing and type of the index worsening-HF event in HFrEF (EF <45%).Key limitations: no overall treatment HR/CI in this abstract · reported HRs describe baseline risk, not treatment effect
Pivotal RCT establishing the exact composite reduction in high-risk HFrEF.
“a primary-outcome event occurred in 897 of 2526 patients (35.5%) in the vericiguat group and in 972 of 2524 patients (38.5%) in the placebo group (hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P = 0.02).”
Panel auditInternal validity: high · scope of inference: Chronic HFrEF (EF <45%, NYHA II-IV) with recent HF hospitalisation or IV diuretics — the exact high-risk worsening HFrEF population of the claim.Key limitations: components (CV death HR 0.93, HFH HR 0.90) individually not clearly significant · modest absolute effect · median follow-up 10.8 months
Affirms the composite reduction and consistency across renal function.
“Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m2 .”
Panel auditInternal validity: high · scope of inference: Consistency of vericiguat's primary-outcome benefit across baseline and changing renal function in worsening HFrEF (eGFR down to 15).Key limitations: no HR or p for the overall effect in this abstract · focus is renal subgroups/interactions · effect magnitude reported elsewhere
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One large, directly on-point RCT with a significant but borderline composite effect, corroborated mainly by its own reanalyses, warrants a Likely rather than Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory RCT. All corpus corroboration is internal to VICTORIA [11], so the claim lacks replication outside a single trial. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second adequately powered, randomised, placebo- or active-controlled trial in high-risk worsening HFrEF with the same composite endpoint.
Open question: Does the composite reduction replicate in a second randomised trial independent of VICTORIA? Why it is still open: Every supporting analysis in the corpus re-examines the single VICTORIA dataset [11]; no independent RCT is present.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19